Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

e patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

Clinical Trials - Recently Filed Application

In the first quarter of 2008, the NCI filed a protocol with the U.S. Food and Drug Administration for a Phase I/II clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R). The trial, which is being carried out at The Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers. These cancer indications were selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill ovarian cancer cells.

Pre-Clinical Trial and Collaborative Program

In the first quarter of 2008, we reported that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled "Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus" appeared online in the January 1, 2008 issue of Clinical Cancer Research.

The purpose of the research study was to investigate whether it was possible to use cyclophosphamide, an immune modulator, to enhance the delivery and replication of the reovirus when delivered intravenously. After testing various doses and dosing regimens of reovirus and cyclophosphamide in mice, a metronomic dosing regimen was developed that resulted in increased survival, high levels of reovirus recovered fr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for Reproductive Medicine ... research in reproductive medicine. In his new role as ... board and will have a voice in furthering the mission ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... California, September 21, ChemAxon, a software solutions provider ... ) today announced an,agreement to maintain the integration ... software suite. Agilent acquired,the Kalabie ELN from Klee ... Klee and ChemAxon to Agilent and ChemAxon. ...
... catheter-related infections, REDMOND, Wash., Sept. 20 ... to enhance the biocompatibility and,performance of current ... deal with Strategic Applications Inc. (SAI), a ... infusion devices.,Healionics, deal with SAI will fully ...
... SAN DIEGO, Sept. 20 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... company,s,President and CEO Theodore Schroeder will present the ... am Eastern Time (8:30 am Pacific,Time) during the ...
Cached Biology Technology:ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 2Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM) 2Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 2
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... pluripotent stem cells were first derived in 2007, scientists have ... which are sourced in early-stage embryos. Both cell types ... body, but their origins in embryonic and adult tissue ... cell types have great potential in basic biological research and ...
... (Sept. 11, 2011) Richard Holbrooke, John Ritter, Lucille ... were all taken by the same silent killer: an ... at The University of Texas Health Science Center at ... found an association with a common genetic variant in ...
... University of Iowa researchers have found high levels of toxic ... Harbor and Ship Canal (IHSC) in East Chicago, Ind. Scientists ... is scheduled to be dredged in spring 2012 to maintain ... of southern Lake Michigan. The study, published online in ...
Cached Biology News:Study reveals critical similarity between two types of do-it-all stem cells 2Study reveals critical similarity between two types of do-it-all stem cells 3UTHealth, BCM researchers find common gene variant associated with aortic dissection 2UTHealth, BCM researchers find common gene variant associated with aortic dissection 3Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 2Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 3
...
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
Biology Products: